A Phase 1b/2, Open-Label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-Small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-Small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Colorectal Cancer
The purpose of this study is to determine the safety and tolerability of entinostat used in
combination with pembrolizumab in patients with Non-small Cell Lung Cancer. Additionally the
purpose of the study is to assess how effective entinostat and pembrolizumab are in
combination in patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch-Repair
Proficient Colorectal Cancer
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.